CB 2679d

Drug Profile

CB 2679d

Alternative Names: CB-FIX; CB2679d; Factor IX - Catalyst Biosciences; FIX-NG; ISU-304

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catalyst Biosciences
  • Developer Catalyst Biosciences; ISU Abxis
  • Class Antihaemorrhagics; Blood coagulation factors; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Blood coagulation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haemophilia B

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Haemophilia-B(Prevention) in USA (SC, Injection)
  • 26 Sep 2017 CB 2679d receives Orphan Drug status for Haemophilia B in USA
  • 11 Sep 2017 Catalyst Biosciences has patent protection for CB 2679d in Europe, Japan, China, Singapore and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top